Crossmark

Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments

Crossref DOI link: https://doi.org/10.1186/s12879-024-09595-4

Published Online: 2024-08-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aparicio, Laura-Amanda Vallejo

García, Victoria Neches

Hernández-Novoa, Beatriz

Casado, Gregorio

Jodar, Ferrán

Pinel, Marco

Velasco, Daniel Callejo
License Information

Text and Data Mining valid from 2024-08-02

Version of Record valid from 2024-08-02
More Information

Article History

Received: 17 January 2024

Accepted: 5 July 2024

First Online: 2 August 2024

Declarations

:

: Laura-Amanda Vallejo Aparicio is employee and holds stocks of GSK group of companies; Victoria Neches García is employee of GSK group of companies; Beatriz Hernández-Novoa is employee and holds stocks of ViiV Healthcare; Gregorio Casado, Ferrán Jodar, Marco Pinel and Daniel Callejo Velasco are employees of IQVIA. IQVIA received fees from ViiV Healthcare for conducting the study.

: All interviews were conducted considering the current regulation on the protection of personal data and pharmacovigilance and in accordance to the EPHMRA Code of Conduct 2022. Given that this study met all requirements to be considered a market research study, according to the EPHMRA Code of Conduct 2022 it did not require Clinical Research Ethics Committee or Independent Review Board approval. HCPs involved received economic compensation for their participation in the project.

Document is current

Any future updates will be listed below